Prevention of Drug Rash From Certain Cancer Therapies Using Tretinoin Cream
NCT ID: NCT01349556
Last Updated: 2014-04-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2011-05-31
2014-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patients taking EGFR-I medications often develop skin irritation and acne-like bumps on their face, chest, and other areas. This rash from EGFR-I's is often treated with moisturizers and topical or oral antibiotics. However, there has not yet been a study looking at a way to prevent this common side effect from occurring, and topical tretinoin may be useful in reducing the rash.
Tretinoin 0.025% cream is approved by the Food and Drug Administration (FDA) for the treatment of acne, acne scarring, and photodamage. It is not approved for use in preventing rashes associated with EGFR-I's.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)
NCT04451330
Prophylactic Treatment of Skin Rash Associated With EGFR Inhibitor Therapy
NCT04239846
Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis
NCT00021294
Absorption and Systematic Pharmacokinetics of Topically Applied IDP-120 Gel
NCT02850003
Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation
NCT04856904
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tretinoin pre-treatment
Tretinoin
tretinoin 0.025% cream
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tretinoin
tretinoin 0.025% cream
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Scheduled to begin treatment with an EGFR inhibitor drug
Exclusion Criteria
* History of bleeding disorder
* History of keloids or large, thick, puffy-looking scars in the last 10 years
* Used topical retinoids in the last year (e.g. tretinoin/Retin-A, adapalene/Differin, tazarotene/Tazorac)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johns Hopkins University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Anna Chien
Assistant Professor, Co-Director, Cutaneous Translational Research Program
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anna L Chien, MD
Role: PRINCIPAL_INVESTIGATOR
Johns Hopkins Dermatology
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NA_00042104
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.